PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

Nick Beije,Wassim Abida,Emmanuel S Antonarakis,Elena Castro,Ronald de Wit,Karim Fizazi,Silke Gillessen,Maha Hussain,Joaquin Mateo,Michael J Morris,David Olmos,Oliver Sartor,Adam Sharp,Christopher J Sweeney,Johann S de Bono

European urology（2023）

引用 1|浏览68

暂无评分

摘要

The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要